Overview
Juliya Fisher is a Dermatologist in New York, New York. Dr. Fisher is rated as an Advanced provider by MediFind in the treatment of Lhermitte-Duclos Disease. Her top areas of expertise are Ruvalcaba Syndrome, Lhermitte-Duclos Disease, Cowden Syndrome, and Bannayan-Riley-Ruvalcaba Syndrome.
Her clinical research consists of co-authoring 16 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Lhermitte-Duclos Disease.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- EPO
- HMO
- PPO
- EPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- EPO
- PPO
- INSURANCE PLAN
- INSURANCE PLAN
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
60 E 56th St, New York, NY 10022
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Markowitz Medical PLLC
Orit Markowitz is a Dermatologist in New York, New York. Dr. Markowitz is rated as an Advanced provider by MediFind in the treatment of Lhermitte-Duclos Disease. Her top areas of expertise are Basal Cell Skin Cancer, Actinic Keratosis, Melanoma, and Ruvalcaba Syndrome.
Daniel Siegel is a Dermatologist in Smithtown, New York. Dr. Siegel is rated as a Distinguished provider by MediFind in the treatment of Lhermitte-Duclos Disease. His top areas of expertise are Actinic Keratosis, Basal Cell Skin Cancer, Acne, and Ruvalcaba Syndrome.
Weill Medical College Of Cornell
Karen Chernoff is a Dermatologist in New York, New York. Dr. Chernoff is rated as an Experienced provider by MediFind in the treatment of Lhermitte-Duclos Disease. Her top areas of expertise are Ruvalcaba Syndrome, Parkes Weber Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, and Cowden Syndrome.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Bannayan-Riley-Ruvalcaba SyndromeDr. Fisher isAdvanced. Learn about Bannayan-Riley-Ruvalcaba Syndrome.
- Cowden SyndromeDr. Fisher isAdvanced. Learn about Cowden Syndrome.
- Lhermitte-Duclos DiseaseDr. Fisher isAdvanced. Learn about Lhermitte-Duclos Disease.
- Ruvalcaba SyndromeDr. Fisher isAdvanced. Learn about Ruvalcaba Syndrome.
- Experienced
- Basal Cell Skin CancerDr. Fisher isExperienced. Learn about Basal Cell Skin Cancer.
- Cutaneous Lupus Erythematosus (CLE)Dr. Fisher isExperienced. Learn about Cutaneous Lupus Erythematosus (CLE).
- Squamous Cell Skin CarcinomaDr. Fisher isExperienced. Learn about Squamous Cell Skin Carcinoma.